Kinsbourne M (1962) Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry 25:271–276

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rudnick E, Khakoo Y, Antunes NL et al (2001) Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the children’s Cancer Group Study. Med Pediatr Oncol 36:612–622

Article  CAS  PubMed  Google Scholar 

Hasegawa S, Matsushige T, Kajimoto M et al (2015) A nationwide survey of opsoclonus–myoclonus syndrome in Japanese children. Brain Dev 37:656–660

Article  PubMed  Google Scholar 

Bar-Sever Z, Biassoni L, Shulkin B et al (2018) Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging 45:2009–2024

Article  CAS  PubMed  Google Scholar 

Rossor T, Yeh EA, Khakoo Y et al (2022) Diagnosis and management of opsoclonus-myoclonus-ataxia syndrome in children. Neurol Neuroimmunol Neuroinflamm 9:e1153

Article  PubMed  PubMed Central  Google Scholar 

Kumar R, Vankadari K, Mittal BR et al (2021) Diagnostic values of 68Ga-labelled DOTANOC PET/CT imaging in pediatric patients presenting with paraneoplastic opsoclonus myoclonus ataxia syndrome. Eur Radiol 31:4587–4594

Article  PubMed  Google Scholar 

Biasotti S, Garaventa A, Villavecchia GP et al (2000) False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol 35:153–155

Article  CAS  PubMed  Google Scholar 

Brunklaus A, Pohl K, Zuberi SM, de Sousa C (2012) Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome. Arch Dis Child 97:461–463

Article  PubMed  Google Scholar 

Sharp SE, Shulkin BL, Gelfand MJ et al (2009) 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 50:1237–1243

Article  PubMed  Google Scholar 

Melzer HI, Coppenrath E, Schmid I et al (2011) 123I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging 38:1648–1658

Article  PubMed  Google Scholar 

Feng L, Li S, Wang C, Yang J (2023) Current status and future perspective on molecular imaging and treatment of neuroblastoma. Semin Nucl Med 53:517–529

Article  PubMed  Google Scholar 

Bleeker G, Tytgat GA, Adam JA et al (2015) 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database Syst Rev:CD009263

Li C, Zhang J, Chen S et al (2018) Prognostic value of metabolic indices and bone marrow uptake pattern on preoperative 18F-FDG PET/CT in pediatric patients with neuroblastoma. Eur J Nucl Med Mol Imaging 45:306–315

Article  PubMed  Google Scholar 

Bar-Sever Z, Keidar Z, Ben-Barak A et al (2007) The incremental value of 18F-FDG PET/CT in paediatric malignancies. Eur J Nucl Med Mol Imaging 34:630–637

Article  PubMed  Google Scholar 

Joshi P, Lele V (2013) Somatostatin receptor positron emission tomography/computed tomography (PET/CT) in the evaluation of opsoclonus-myoclonus ataxia syndrome. Indian J Nucl Med 28:108–111

Article  PubMed  PubMed Central  Google Scholar 

Matthay KK, Blaes F, Hero B et al (2005) Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett 228:275–282

Article  CAS  PubMed  Google Scholar 

Pranzatelli MR, Tate ED, McGee NR (2017) Demographic, clinical, and immunologic features of 389 children with opsoclonus-myoclonus syndrome: a cross-sectional study. Front Neurol 8:468

Article  PubMed  PubMed Central  Google Scholar 

Ki Pang K, de Sousa C, Lang B, Pike MG (2010) A prospective study of the presentation and management of dancing eye syndrome/opsoclonus–myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol 14:156–161

Article  PubMed  Google Scholar 

Blaes F, Dharmalingam B (2016) Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment. Expert Rev Neurother 16:641–648

Article  CAS  PubMed  Google Scholar 

Russo C, Cohn SL, Petruzzi MJ, de Alarcon PA (1997) Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 28:284–288

Article  CAS  PubMed  Google Scholar 

Koh PS, Raffensperger JG, Berry S et al (1994) Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. J Pediatr 125:712–716

Article  CAS  PubMed  Google Scholar 

Mitchell WG, Davalos-Gonzalez Y, Brumm VL et al (2002) Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics 109:86–98

Article  PubMed  Google Scholar 

Hayward K, Jeremy RJ, Jenkins S et al (2001) Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J Pediatr 139:552–559

Article  CAS  PubMed  Google Scholar 

Martiniova L, Perera SM, Brouwers FM et al (2011) Increased uptake of [123I]meta-iodobenzylguanidine, [18F]fluorodopamine, and [3H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. Endocr Relat Cancer 18:143–157

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rothenberg AB, Berdon WE, D’Angio GJ et al (2009) The association between neuroblastoma and opsoclonus-myoclonus syndrome: a historical review. Pediatr Radiol 39:723–726

Article  PubMed  Google Scholar 

Cohn SL, Pearson AD, London WB et al (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27:289–297

Article  PubMed  PubMed Central  Google Scholar 

Altman AJ, Baehner RL (1976) Favorable prognosis for survival in children with coincident opso-myoclonus and neuroblastoma. Cancer 37:846–852

Article  CAS  PubMed  Google Scholar 

Simon T, Hero B, Hunneman DH, Berthold F (2003) Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer 39:1899–1903

Article  CAS  PubMed  Google Scholar